Cargando…

Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections

The rise in antimicrobial resistance (AMR) has complicated the management of urinary tract infections (UTIs). The objective of this study was to evaluate the antimicrobial susceptibility patterns of Escherichia coli and Klebsiella pneumoniae. Design: prospective observational study. Bacteria were cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Miranda-Novales, Guadalupe, Flores-Moreno, Karen, López-Vidal, Yolanda, Ponce de León-Rosales, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687036/
https://www.ncbi.nlm.nih.gov/pubmed/36421299
http://dx.doi.org/10.3390/antibiotics11111656
_version_ 1784835904050823168
author Miranda-Novales, Guadalupe
Flores-Moreno, Karen
López-Vidal, Yolanda
Ponce de León-Rosales, Samuel
author_facet Miranda-Novales, Guadalupe
Flores-Moreno, Karen
López-Vidal, Yolanda
Ponce de León-Rosales, Samuel
author_sort Miranda-Novales, Guadalupe
collection PubMed
description The rise in antimicrobial resistance (AMR) has complicated the management of urinary tract infections (UTIs). The objective of this study was to evaluate the antimicrobial susceptibility patterns of Escherichia coli and Klebsiella pneumoniae. Design: prospective observational study. Bacteria were classified as susceptible or resistant to ampicillin-sulbactam, amikacin, gentamicin, ciprofloxacin, norfloxacin, nitrofurantoin, trimethoprim-sulfamethoxazole (TMP/SMZ), ertapenem, meropenem, and fosfomycin. The sensitivity to fosfomycin and chloramphenicol was evaluated by the disk diffusion method. Statistical analysis: the chi-square test and Fisher’s exact test were used to compare differences between categories. A p value < 0.05 was considered statistically significant. Isolates were collected from January 2019 to November 2020 from 21 hospitals and laboratories. A total of 238 isolates were received: a total of 156 E. coli isolates and 82 K. pneumoniae isolates. The majority were community-acquired infections (64.1%). Resistance was >20% for beta-lactams, aminoglycosides, fluoroquinolones, and TMP/SMZ. For E. coli isolates, resistance was <20% for amikacin, fosfomycin, and nitrofurantoin; for K. pneumoniae, amikacin, fosfomycin, chloramphenicol, and norfloxacin. All were susceptible to carbapenems. K. pneumoniae isolates registered a higher proportion of extensively drug-resistant bacteria in comparison with E. coli (p = 0.0004). In total, multidrug-resistant bacteria represented 61% of all isolates. Isolates demonstrated high resistance to beta-lactams, fluoro-quinolones, and TMP/SMZ.
format Online
Article
Text
id pubmed-9687036
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96870362022-11-25 Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections Miranda-Novales, Guadalupe Flores-Moreno, Karen López-Vidal, Yolanda Ponce de León-Rosales, Samuel Antibiotics (Basel) Article The rise in antimicrobial resistance (AMR) has complicated the management of urinary tract infections (UTIs). The objective of this study was to evaluate the antimicrobial susceptibility patterns of Escherichia coli and Klebsiella pneumoniae. Design: prospective observational study. Bacteria were classified as susceptible or resistant to ampicillin-sulbactam, amikacin, gentamicin, ciprofloxacin, norfloxacin, nitrofurantoin, trimethoprim-sulfamethoxazole (TMP/SMZ), ertapenem, meropenem, and fosfomycin. The sensitivity to fosfomycin and chloramphenicol was evaluated by the disk diffusion method. Statistical analysis: the chi-square test and Fisher’s exact test were used to compare differences between categories. A p value < 0.05 was considered statistically significant. Isolates were collected from January 2019 to November 2020 from 21 hospitals and laboratories. A total of 238 isolates were received: a total of 156 E. coli isolates and 82 K. pneumoniae isolates. The majority were community-acquired infections (64.1%). Resistance was >20% for beta-lactams, aminoglycosides, fluoroquinolones, and TMP/SMZ. For E. coli isolates, resistance was <20% for amikacin, fosfomycin, and nitrofurantoin; for K. pneumoniae, amikacin, fosfomycin, chloramphenicol, and norfloxacin. All were susceptible to carbapenems. K. pneumoniae isolates registered a higher proportion of extensively drug-resistant bacteria in comparison with E. coli (p = 0.0004). In total, multidrug-resistant bacteria represented 61% of all isolates. Isolates demonstrated high resistance to beta-lactams, fluoro-quinolones, and TMP/SMZ. MDPI 2022-11-18 /pmc/articles/PMC9687036/ /pubmed/36421299 http://dx.doi.org/10.3390/antibiotics11111656 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Miranda-Novales, Guadalupe
Flores-Moreno, Karen
López-Vidal, Yolanda
Ponce de León-Rosales, Samuel
Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections
title Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections
title_full Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections
title_fullStr Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections
title_full_unstemmed Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections
title_short Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections
title_sort limited therapeutic options in mexico for the treatment of urinary tract infections
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687036/
https://www.ncbi.nlm.nih.gov/pubmed/36421299
http://dx.doi.org/10.3390/antibiotics11111656
work_keys_str_mv AT mirandanovalesguadalupe limitedtherapeuticoptionsinmexicoforthetreatmentofurinarytractinfections
AT floresmorenokaren limitedtherapeuticoptionsinmexicoforthetreatmentofurinarytractinfections
AT lopezvidalyolanda limitedtherapeuticoptionsinmexicoforthetreatmentofurinarytractinfections
AT poncedeleonrosalessamuel limitedtherapeuticoptionsinmexicoforthetreatmentofurinarytractinfections
AT limitedtherapeuticoptionsinmexicoforthetreatmentofurinarytractinfections